Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon
Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C
virus (HCV) ribonucleic acid (RNA) levels